日韩精品久久一区二区三区_亚洲色图p_亚洲综合在线最大成人_国产中出在线观看_日韩免费_亚洲综合在线一区

Global EditionASIA 中文雙語Fran?ais
Business
Home / Business / State Council News

Nation issues new anti-monopoly guidelines for pharma sector

By Li Jiaying | chinadaily.com.cn | Updated: 2025-01-24 21:04
Share
Share - WeChat
Pharmacists dispense drugs at a hospital in Huzhou, Zhejiang province, in August. YI FAN/FOR CHINA DAILY

In an effort to safeguard fair market competition and protect consumer interests, the State Council's anti-monopoly commission officially issued new anti-monopoly guidelines on Friday targeting the pharmaceutical sector. 

A key highlight of the guidelines lies in the involvement of online platforms' monopolistic regulations. Given the rapid growth of online medical consultations and pharmaceutical e-commerce, the guidelines, for the first time, incorporate measures to address monopolistic practices in online medicine businesses, prohibiting platforms from engaging in the misuse of data, algorithms or platform rules.

The broad scope of the new guidelines also merits attention, which encompasses the entire pharmaceutical product chain — including traditional Chinese medicine, chemical drugs and biological products — compared to the previous version, which was largely concentrated in the limited realm of chemical active pharmaceutical ingredients (APIs).

"The pharmaceutical industry is highly technology-driven. Besides APIs, it also includes innovative drugs, patented medicines and generics. Every stage — from procurement and R&D to production, distribution and generic development — involves significant technological advancements and related protective strategies," said Zhou Wei, deputy director of the health law research center at Wuhan University, in an earlier interview. 

To further combat "false innovation", the guidelines also address a new type of patent monopoly behavior known as "product hopping". 

Product hopping refers to a strategy employed by original drug manufacturers to avoid or reduce competition from generic drugs, which mostly occurs shortly before the expiration of a patented drug and the entry of its generic counterpart and if applied inappropriately, could constitute an abuse of market dominance.

Factors for evaluation include whether the new patented drug represents a non-substantial improvement and whether the transition hinders or delays the entry of generics into the market, according to the guidelines.

"This is not about restricting the development of patented drugs but about regulating false innovation that fails to significantly improve a drug's efficacy, safety or utility," Zhou said.

Comprising seven chapters and 55 articles, the guidelines aim to provide detailed interpretations of monopolistic practices, enforcement principles and criteria for determining violations, offering a comprehensive framework to tackle anti-competitive behaviors in the pharmaceutical industry.

Top
BACK TO THE TOP
English
Copyright 1995 - . All rights reserved. The content (including but not limited to text, photo, multimedia information, etc) published in this site belongs to China Daily Information Co (CDIC). Without written authorization from CDIC, such content shall not be republished or used in any form. Note: Browsers with 1024*768 or higher resolution are suggested for this site.
License for publishing multimedia online 0108263

Registration Number: 130349
FOLLOW US
CLOSE
 
主站蜘蛛池模板: 99精品大香线蕉线伊人久久久 | 欧美激情视频二区三区 | 三上悠亚2022最新新作番号 | 国偷自产av一区二区三区 | 国产99久久精品 | 999毛片 | 亚洲欧美中文字幕 | 欧美在线一区二区三区 | 免费亚洲黄色 | 福利视频网页 | 亚洲精品一区在线观看 | 国产瑟瑟视频 | 日韩操操操 | 激情五月社区 | 精品成人| 狠狠干伊人网 | 国产成人免费全部网站 | 久久亚洲国产成人影院 | 老司机福利在线视频 | 夜精品A片观看无码一区二区 | 12345国产精品高清在线 | 久久综合九色综合91 | 欧美另类色图 | 国产欧美一区二区三区免费看 | 亚洲高清在线看 | 免费看黄网址 | 欧美日韩一区二区视频在线观看 | 国产成人精品福利站 | youjizz欧美 | 久久99精品这里精品动漫6 | 久久国产高清视频 | 久操伊人 | 日本理论片中文在线观看2828 | 日本三级网| 免费国产一级特黄久久 | 亚洲国产精品日韩高清秒播 | 国产亚洲精品久久久久久一区二区 | 国产毛片一级 | 久久久91精品国产一区二区三区 | 日本不卡一区在线 | 亚洲欧美日韩在线观看播放 |